Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 20/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21466836 | 1.00 | IDH1 (1.00) | IDH1NR1I2CYP3A4 | |
| SCHEMBL17814454 | 1.00 | IDH1 (1.00) | IDH1NR1I2CYP3A4 | |
| SCHEMBL21316757 | 0.94 | IDH1 (1.00) | IDH1NR1I2CYP3A4 | |
| SCHEMBL17814492 | 0.94 | IDH1 (1.00) | IDH1NR1I2CYP3A4 | |
| SCHEMBL18797413 | 0.94 | IDH1 (1.00) | IDH1NR1I2CYP3A4 | |
| SCHEMBL22184803 | 0.94 | IDH1 (1.00) | IDH1NR1I2CYP3A4 | |
| SCHEMBL22184802 | 0.94 | IDH1 (1.00) | IDH1NR1I2CYP3A4 | |
| SCHEMBL21466897 | 0.94 | IDH1 (1.00) | IDH1NR1I2CYP3A4 | |
| SCHEMBL18797299 | 0.94 | IDH1 (1.00) | IDH1NR1I2CYP3A4 | |
| SCHEMBL19741777 | 0.94 | IDH1 (1.00) | IDH1NR1I2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3226688-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME (US) | 2020-07-01 | — | — | EP | disclosed |
| US-20170369507-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2017-12-28 | — | — | US | disclosed |
| WO-2016089797-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | MERCK SHARP & DOHME CORP. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369507-A1 | NOVEL TRICYCLIC COMPOUNDS AS INHIBITORS OF MUTANT IDH ENZYMES | IDH3A, IDH3B, IDH2 | IDH1 4/4885NR1I2 1302/4885CYP3A4 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.